Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study

BMJ Open

Volumn 1, Issue 1, 2011, Pages

  Skeie, Ivar ^a,b   Brekke, Mette ^b   Gossop, Michael ^b,c   Lindbaek, Morten ^b   Reinertsen, Even ^d   Thoresen, Magne ^b   Waal, Helge ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Innlandet Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874111416     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000130     Document Type: Article

References (42)

1. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82:250-66.
2. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005;24:411-18.
3. Popova S, Rehm J, Patra J, et al. Illegal drug-attributable morbidity in Canada 2002. Drug Alcohol Rev 2007;26:251-63.
4. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33:587-95.
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arc Gen Psychiatry 1994;51:8-19.
6. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-18.
7. Millson PE, Challacombe L, Villeneuve PJ, et al. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health 2004;95:99-103.
8. Puigdollers E, Domingo-Salvany A, Brugal MT, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse 2004;39:1353-68.
9. Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005;100:981-9.
10. Darke S, Degenhardt L, Mattick R. Mortality Amongst Illicit Drug Users: Epidemiology, Causes and Intervention. Cambridge: Cambridge University Press, 2007.
11. Reimer J, Lorenzen J, Baetz B, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007;22:80-5.
12. Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000;40:176-83.
13. Hope V, Kimber J, Vickerman P, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis 2008;8:120.
14. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006;16:198-202.
15. WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization, 2009.
16. Fischer B, Rehm J, Kim G, et al. Eyes wide shut?eA conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005;11:1-9; discussion 10-14.
17. Darke S, Ross J, Teesson M. The Australian Treatment Outcome Study (ATOS): what have we learnt about treatment for heroin dependence? Drug Alcohol Rev 2007;26:49-54.
18. Gowing L, Farrell M, Bornemann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008;(2):CD004145.
19. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockadeea medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians 1966;79:122-36.
20. Kreek MJ. Tolerance and dependence: implications for the pharmacological treatment of addiction. In: Harris LS, ed, NIDA Research Monograph 76-Problems of Drug Dependence 1986: Proceeding of the 48th Annual Scientific Meeting The Committee On Problems of Drug Dedpendence. Rockville: US Department of Health and Human Services, 1987:53-62.
21. Wittchen HU, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008;95:245-57.
22. Stenbacka M, Leifman A, Romelsjo A. The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status. Subst Use Misuse 1998;33:2819-34.
23. Romelsjo A, Engdahl B, Stenbacka M, et al. Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? Addiction 2010;105:1625-32.
24. Skeie I, Brekke M, Lindbaek M, et al. Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC public health 2008;8:43.
25. Waal H, Clausen T, Håseth A, et al. Seraf Rapport 1/2010 (revidert utgave) Siste år med gamle retningslinjer Statusrapport 2009. Oslo: Norwegian Centre for Addiction Research, 2010.
26. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008;94:151-7.
27. Fugelstad A, Stenbacka M, Leifman A, et al. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007;102:406-12.
28. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;341: c3172.
29. Caplehorn JR, Dalton MS, Haldar F, et al. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996;31:177-96.
30. Dolan KA, Shearer J, White B, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820-8.
31. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990;82:223-7.
32. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998;52:257-60.
33. Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475.
34. Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102:1954-9.
35. Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
36. Spijkerman IJ, van Ameijden EJ, Mientjes GH, et al. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 1996;49:1149-54.
37. Hope VD, Marongiu A, Parry JV, et al. The extent of injection site infection in injecting drug users: findings from a national surveillance study. Epidemiol Infect 2010;138:1510-18.
38. Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004;99:697-707.
39. Millson P, Challacombe L, Villeneuve PJ, et al. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Euro Addict Res 2006;12:74-82.
40. Cullen W, O'Brien S, O'Carroll A, et al. Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care. BMC Fam Pract 2009;10:25.
41. Williamson A, Darke S, Ross J, et al. Changes and predictors of change in the physical health status of heroin users over 24 months. Addiction 2009;104:465-70.
42. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Euro Addict Res 2007;13:66-73.